Adimab Inside: Polaris, Orbimed Back Antibody Attack On Novel Alzheimer’s Biology
This article was originally published in The Pink Sheet Daily
Alzheimer’s-focused Alector combines its scientific founders’ biological insight with antibody discovery technology from Adimab, allowing Adimab’s backers and executives to pursue multiple but distinct bets on the success of their platform.
You may also be interested in...
The antibody engineering company Adimab LLC has signed two non-exclusive deals that should put the small biotech firmly in the black. The deals with GSK and Biogen, announced July 26, are Adimab’s first in which it transfers its technology for broad use by partners.
As executives and investors scramble to find business models that more closely link investment and return, a handful of technology firms have alit on variations of a capital-efficient strategy: let someone else do the development dirty work.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.